CT Image of Consolidation and Ground-Glass Opacification (GGO) of COVID-19 in Diabetic Patient

Katsunori Ogura; Hiroshi Bando; Yoshinobu Kato; Hisako Yamashita; Yoshikane Kato

doi:10.36502/2023/ASJBCCR.6299

CT Image of Consolidation and Ground-Glass Opacification (GGO) of COVID-19 in Diabetic Patient | Abstract

Asploro Journal of Biomedical and Clinical Case Reports

ISSN: 2582-0370

Article Type: Case Report

DOI: 10.36502/2023/ASJBCCR.6299

Asp Biomed Clin Case Rep. 2023 May 20;6(2):95-102

Full Text HTML

Full Text PDF

Katsunori Ogura¹, Hiroshi Bando^1,2ID*, Yoshinobu Kato¹, Hisako Yamashita¹, Yoshikane Kato¹
¹Kanaiso Hospital, Komatsushima, Tokushima, Japan
²Tokushima University/Medical research, Tokushima, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 18 April 2023; Accepted date: 13 May 2023; Published date: 20 May 2023

Citation: Ogura K, Bando H, Kato Y, Yamashita H, Kato Y. CT Image of Consolidation and Ground-Glass Opacification (GGO) of COVID-19 in Diabetic Patient. Asp Biomed Clin Case Rep. 2023 May 20;6(2):95-102.

Copyright © 2023 Ogura K, Bando H, Kato Y, Yamashita H, Kato Y. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Real-Time Polymerase Chain Reaction, COVID-19, EquMet (vildagliptin/metformin), Imeglimin (Twymeeg), Gastro-Intestinal Adverse Effects

Abbreviations: RT-PCR: Real-Time Polymerase Chain Reaction; GIAEs: Gastro-Intestinal Adverse Effects

Abstract

The case involves a 70-year-old female with Type 2 Diabetes (T2D) who had been prescribed EquMet (vildagliptin/metformin) and had a stable HbA1c. In August 2022, she tested positive for real-time polymerase chain reaction (RT-PCR) without showing any symptoms. By November 2022, her HbA1c had increased to 7.4%, and a chest CT scan revealed a consolidation lesion in her left lower lung, suggesting post-inflammatory pathology of COVID-19. Imeglimin (Twemeeg) was added to her treatment regimen, and it proved effective, resulting in a 0.9% reduction in HbA1c over 4 months without any gastrointestinal adverse effects (GIAEs). The combined treatment of EquMet and Twymeeg was effective, and the interrelationship between T2D and COVID-19 will be followed up.